Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Fig. 3

ALRN-6924 combined with paclitaxel reactivates p53 and induces cell cycle arrest and apoptosis in vitro. a Cell cycle analysis was carried out by flow cytometry after 24-h treatment with vehicle, ALRN-6924 (10 μM), paclitaxel (1 μM), or combination of both. Percentages of cells in Sub-G1, G0-G1, S, and G2-M phases of cell cycle are depicted. b Flow cytometry analysis of Annexin V-positive cells after treatment for 72 h by vehicle, ALRN-6924 (10 μM), paclitaxel (1 μM), or combination of both in both MCF-7 and ZR-75-1. Mean ± SD (n = 3) values are shown. c Immunoblotting of p53, p21, Mdm2, and p-Histone-H3 (Ser10). MCF-7 and ZR-75 were treated with vehicle control, ALRN-6924 at 10 μM, or paclitaxel 0.1, 1 μM, or combination of both for 24 h

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us